Published in J Natl Cancer Inst on August 01, 1970
The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med (1978) 1.96
Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med (1980) 1.72
The induction of tumours in the guinea-pig with methylcholanthrene and diethylnitrosamine and their propagation in vivo and in vitro. Br J Cancer (1973) 0.92
Antigenicity of C 3 H mammary carcinoma in isogenetic hosts: preliminary studies. J Natl Med Assoc (1973) 0.75
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Complement fixation on cell surfaces by 19S and 7S antibodies. Science (1965) 4.04
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res (1994) 3.62
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature (1987) 3.46
Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol (1965) 3.42
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol (1999) 3.14
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Complement and Hemolysis. Science (1963) 2.73
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet (1994) 2.52
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA (1995) 2.43
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
BCG and cancer (first of two parts). N Engl J Med (1974) 2.13
Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol (1974) 2.07
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
Forssman antigen and antibody: preparation of water soluble antigen and measurement of antibody concentration by precipitin analysis, by C'1a fixation and by hemolytic activity. J Immunol (1966) 1.95
Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res (1995) 1.91
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst (1974) 1.82
Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene (1995) 1.82
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody. J Immunol (1966) 1.80
Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science (1971) 1.80
Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst (1972) 1.75
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst (1974) 1.74
BCG and cancer. N Engl J Med (1974) 1.66
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am (2006) 1.64
Tumor immunity produced by the intradermal inoculation of living tumor cells and living Mycobacterium bovis (strain BCG). Science (1970) 1.64
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4. J Immunol (1971) 1.60
Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res (1987) 1.59
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol (2001) 1.58
Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A (1992) 1.56
Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration. Int J Cancer (1977) 1.56
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst (1972) 1.47
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res (1998) 1.46
Tumor-specific antigen solubilized by hypertonic potassium chloride. J Natl Cancer Inst (1971) 1.46
Synthesis of the first component of human complement in vitro. J Exp Med (1968) 1.44
Production of the second (C2) and fourth (C4) components of guinea pig complement by single peritoneal cells: evidence that one cell may produce both components. J Immunol (1972) 1.44
Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet (1995) 1.42
Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst (1974) 1.42
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest (1999) 1.41
Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res (1991) 1.38
Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J Natl Cancer Inst (1974) 1.38
Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet (2000) 1.33
Granuloma formation in lungs of mice after intravenous administration of emulsified trehalose-6,6'-dimycolate (cord factor): reaction intensity depends on size distribution of the oil droplets. Infect Immun (1977) 1.32
Tumor suppression by cell walls of mycobacterium bovis attached to oil droplets. J Natl Cancer Inst (1972) 1.32
In vitro synthesis of the first component of complement by guinea pig small intestine. Proc Natl Acad Sci U S A (1966) 1.30
A guinea pig model for tumor immunology. A summary. Isr J Med Sci (1973) 1.29
Antigenicity of a new diethylnitrosamine-induced transplantable guinea pig hepatoma: pathology and formation of ascites variant. J Natl Cancer Inst (1968) 1.28
Tumor-graft rejection in syngeneic guinea pigs: evidence for a two-step mechanism. J Natl Cancer Inst (1970) 1.27
The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol (1992) 1.27
Mouse complement: the effect of sex hormones and castration on two of the late-acting components. J Exp Med (1967) 1.26
Purification of the first component of complement by zonal ultracentrifugation. J Immunol (1969) 1.26